Reuters -- GlaxoSmithKline has challenged a biotech patent held by Roche’s Genentech unit in a bid to give a clear run to its experimental cancer and arthritis drug Arzerra, being developed with Genmab (GEN.CO).
Reuters -- GlaxoSmithKline has challenged a biotech patent held by Roche’s Genentech unit in a bid to give a clear run to its experimental cancer and arthritis drug Arzerra, being developed with Genmab (GEN.CO).
